If you take a GLP-1 medicine and have been hospitalised by acute pancreatitis, the Yellow Card Biobank wants to hear from you聽
GLP-1 medicines are licensed for Type 2 diabetes and weight management, and include the branded products Ozempic, Mounjaro and Wegovy聽
The pioneering , launched by the Medicines and Healthcare products Regulatory Agency (MHRA) and Genomics England, will start investigating whether the risk of acute pancreatitis (inflamed pancreas) from GLP-1 injections for weight loss and Type 2 diabetes may be influenced by an individual바카라 사이트檚 genes.聽바카라 사이트�
Patients who have been hospitalised with acute pancreatitis suspected to be related to glucagon-like peptide-1 receptor agonists (GLP-1 medicines), such as Ozempic and Mounjaro, are being asked to report it to the MHRA바카라 사이트檚 . These medicines are sometimes referred to colloquially as 바카라 사이트渟kinny jabs바카라 사이트� although they are licensed for both weight loss and Type 2 diabetes.바카라 사이트�바카라 사이트�
Healthcare professionals are also being asked to help recruit for the study by reporting Yellow Cards on behalf of patients experiencing acute pancreatitis while taking GLP-1 medicines.바카라 사이트繏繏�
When a Yellow Card report is received, the MHRA will contact patients to ask if they would be willing to take part in the Biobank study. This would involve providing further information and submitting a saliva or spit sample which will be used to explore whether some people are at a higher risk of acute pancreatitis when taking these medicines due to their genetic makeup, with the overall aim of reducing the occurrence of these side effects in the future.바카라 사이트�
Dr Alison Cave, MHRA Chief Safety Officer said:바카라 사이트�
Evidence shows that almost a third of side effects to medicines could be prevented with the introduction of genetic testing. It is predicted that adverse drug reactions cost the NHS more than 拢2.2 billion a year in hospital stays alone.바카라 사이트繏繏�
Information from the Yellow Card Biobank will help us to better predict those most at risk of adverse reactions - enabling patients across the UK to receive the safest medicine for them, based on their genetic makeup.바카라 사이트�
To help us help you, we바카라 사이트檙e asking anyone who has been hospitalised with acute pancreatitis while taking a GLP-1 medicine to report this to us via our Yellow Card scheme.바카라 사이트�바카라 사이트�
Even if you don바카라 사이트檛 meet the criteria for this phase of the biobank study, information about your reaction to a medication is always extremely valuable in helping to improve patient safety.
Professor Matt Brown, Chief Scientific Officer of Genomics England, said: 바카라 사이트犫繏�
GLP-1 medicines like Ozempic and Wegovy바카라 사이트痟ave been making headlines, but like all medicines there can be a risk of serious side effects. We believe there is real potential to minimise these with many adverse reactions having a genetic cause.바카라 사이트�바카라 사이트�
This next step in our partnership with the MHRA will generate data and evidence for safer and more effective treatment through more personalised approaches to prescription, supporting a shift towards an increasingly prevention-focused healthcare system.
Although infrequent, acute pancreatitis has been reported with GLP-1 medicines. This can be serious. The main symptom of this is severe pain in the stomach that radiates to the back and does not go away. Anyone who experiences this should seek immediate medical help.바카라 사이트�
The Yellow Card Biobank aims to help understand how a patient바카라 사이트檚 genetic makeup can impact the safety of their medicines and forms part of a long-term vision for more personalised medicine approaches. Approved scientists will use the genetic information in the Yellow Card Biobank to investigate whether a side effect from a medicine was caused by a specific genetic trait. Ultimately this will enable healthcare professionals to personalise prescriptions using rapid screening tests, so patients across the UK will receive the safest medication for them, based on their genetic makeup.바카라 사이트�
Side effects continue to be a significant burden on the NHS and studies have shown they account for one in six hospital admissions. Screening tests provide the opportunity to reduce the likelihood of these adverse drug reactions from happening.바카라 사이트�
The MHRA will request a saliva sample from everyone who takes part in the Yellow Card Biobank study. Saliva testing kits will be posted to participants at their home. It is quick and easy to provide a sample. Instructions will be provided along with a prepaid postage envelope. 바카라 사이트�
Notes to Editors바카라 사이트�
-
Glucagon-like peptide-1 receptor agonists (GLP-1 or GLP-1 RAs) are medicines that help people feel fuller by mimicking a natural hormone released after eating. Some newer medicines, like Mounjaro, also act on a second hormone involved in appetite and blood sugar control. These have been referred to in the media as 바카라 사이트渨eight loss injections바카라 사이트� or 바카라 사이트渟kinny jabs바카라 사이트�, but not all are authorised for weight loss.聽바카라 사이트�바카라 사이트�
-
The Yellow Card Biobank is looking to recruit patients across the UK aged 18 or over who were hospitalised after experiencing acute pancreatitis after taking a GLP-1 medicine. If you are unsure whether you are or were taking one of these medicines, check the label to see what the active ingredient is 바카라 사이트� it should say semaglutide, liraglutide, lixisenatide, dulaglutide, exenatide or trizepatide. Alternatively, speak to a healthcare professional.바카라 사이트�
-
Healthcare professionals are asked to report Yellow Cards on behalf of patients who are taking GLP-1 medicines (including dual GLP-1 and GIP agonists) and experience acute pancreatitis. While completing the Yellow Card, select 바카라 사이트淵es바카라 사이트� when asked if you agree to be contacted about the Yellow Card Biobank. If the patient is eligible, the team will be in touch to ask for your help in contacting the patient. The Yellow Card Biobank also works directly with healthcare professionals to refer patients, please see the website for more information or to get in touch with the team.바카라 사이트犫繏�
-
The MHRA has issued recent on how to use these medicines safely.바카라 사이트�바카라 사이트�
-
The first phase of the Biobank campaign was to recruit patients who experienced severe reactions and 바카라 사이트繏繏�
-
The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating all medicines and medical devices in the UK by ensuring they work and are acceptably safe.바카라 사이트� All our work is underpinned by robust and fact-based judgements to ensure that the benefits justify any risks.바카라 사이트�
-
The MHRA is an executive agency of the Department of Health and Social Care.바카라 사이트�
-
is a company established and wholly owned by the Department for Health and Social Care. It is a global leader in enabling genomic medicine and research, focused on creating a world where everyone benefits from genomic healthcare. Building on the 100,000 Genomes Project, it supports the NHS바카라 사이트檚 world-first national whole genome sequencing service and runs the growing National Genomic Research Library alongside delivering numerous major genomics initiatives.바카라 사이트�
-
This project forms part of the 바카라 사이트바카라 사이트檚바카라 사이트�.바카라 사이트犫繏�
-
For media enquiries, please contact the바카라 사이트�newsdesk@mhra.gov.uk or call 020 3080 7651
Updates to this page
-
Updated to change lead image
-
First published.